Emergent BioSolutions Inc. announced on November 11 that its Board of Directors has authorized management to repurchase up to $250 million of the company’s common stock from time to time on the open market or in privately negotiated transactions. This repurchases authorization expires on November 11, 2022. .
Read more about this news here.
